Men's Health

When, in the early 2010’s Menarini Group, entered the Andrology Therapeutic Area acquiring the rights for the first European approved oral treatment for Premature Ejaculation (PE), the Company unveiled for the very first time the burden of one the most common male sexual disease.

In order to offer to both physicians and patients a full therapeutic armamentarium in Andrology, starting from 2014, Menarini Group has been committed in Erectile Dysfunction (ED) treatment, too.

In less than 10 years, Menarini Group became one of the most valuable partner in Andrology for both general practitioners, specialists and patients.

Nowadays Menarini Group is involved in Andrology with therapeutic solutions targeting PE, ED and BPH (Benign Prostatic Hyperplasia).

Premature Ejaculation (PE) and Erectile Dysfunction (ED) are ones of the main complaints in Andrology.

Premature Ejaculation

PE is a condition characterized by the difficulty or inability to exercise voluntary control over ejaculation and by negative consequence for both suffering men and their partners. Nowadays, a variable number of men suffers from this disease, with an incidence of 1 out of 5 adult men in Europe and higher in other Countries of the World, regardless of age.

Patients suffering from PE are often unwilling to discuss their symptoms and many physicians do not know about effective treatments. As a result, patients may be misdiagnosed or mistreated. Men with PE are more likely to report low satisfaction with their sexual relationship, low satisfaction with sexual intercourse, difficulty relaxing during intercourse, and less frequent intercourse.

Erectile Dysfunction

Differently, ED is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Erectile Dysfunction may affect physical and psychosocial health and may have a significant impact on the quality of life (QoL) of sufferers and their partners’.

Erectile Dysfunction shares both unmodifiable and modifiable common risk factors with cardiovascular diseases (e.g., obesity, diabetes mellitus, dyslipidemia, metabolic syndrome, lack of exercise, and smoking).

Epidemiological data reveal that about 152 million men were affected around the world in 1995 and according to estimates, this figure could rise to 322 million by 2025.